AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9101010 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin with insulin
Number of subjects: 0
Study 9101010 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 0
Study 8287573 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen replacement therapy (oestradiol valerate 2 mg/day)
Number of subjects: 17
Study 8287573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3449561 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution of vancomycin
Number of subjects: 0
Study 3449561 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-solid matrix capsules of vancomycin
Number of subjects: 0
Study 29076376 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 100 mg and metformin 500 mg
Number of subjects: 202
Study 29076376 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 2.5 mg
Number of subjects: 202
Study 27210844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan's bent leg raise (BLR)
Number of subjects: 31
Study 27210844 — intervention group
Group type: EXPERIMENTAL
Intervention: Butler's neural tissue mobilization (NTM)
Number of subjects: 31
Study 24903122 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) for skin cancer treatment options and value clarification activity
Number of subjects: 0
Study 24903122 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DA experience)
Number of subjects: 0
Study 23470322 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention program for physical activity
Number of subjects: 368
Study 23470322 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 368
Study 21178836 — intervention group
Group type: EXPERIMENTAL
Intervention: Comic Book of the Back (intervention group)
Number of subjects: 497
Study 21178836 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 497
Study 18316673 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (TCD-12K)
Number of subjects: 92
Study 18316673 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 92
Study 18316673 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (TCD-18K)
Number of subjects: 92
Study 16816509 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma derived hepatitis B vaccine (pre‐S and S antigens)
Number of subjects: 159
Study 16816509 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (S antigen only)
Number of subjects: 159
Study 16816509 — intervention group
Group type: EXPERIMENTAL
Intervention: 0, 1, 6 schedule
Number of subjects: 159
Study 16816509 — intervention group
Group type: COMPARATOR
Intervention: 0, 1, 2 schedule
Number of subjects: 159
Study 14627860 — intervention group
Group type: EXPERIMENTAL
Intervention: 644 mg/d DT56a
Number of subjects: 98
Study 14627860 — intervention group
Group type: COMPARATOR
Intervention: 344 mg/d DT56a supplemented with calcium
Number of subjects: 98
Study 10746534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 2000
Study 10746534 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5%-Mepivacaine 2%
Number of subjects: 2000
Study 9111487 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with standardized allergen extracts
Number of subjects: 22
Study 9111487 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched, monosensitized to HDM)
Number of subjects: 22
Study 1587966 — intervention group
Group type: EXPERIMENTAL
Intervention: IV omeprazole 40 mg over 2.5 min
Number of subjects: 8
Study 1587966 — intervention group
Group type: EXPERIMENTAL
Intervention: IV omeprazole 80 mg over 5 min
Number of subjects: 8
Study 1587966 — intervention group
Group type: COMPARATOR
Intervention: IV placebo over 2.5 min
Number of subjects: 8
Study 2941404 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 200 mg intramuscularly
Number of subjects: 30
Study 2941404 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 3 g orally
Number of subjects: 30
Study 2941404 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 30
Study 30326952 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly malaria prophylaxis (MMP) with dihydroartemisinin-piperaquine and weekly primaquine for 12 weeks
Number of subjects: 1000
Study 30326952 — intervention group
Group type: COMPARATOR
Intervention: Focused screening and treating (FSAT) following current Cambodian national treatment guidelines
Number of subjects: 1000
Study 30326952 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated clothing
Number of subjects: 1000
Study 30326952 — intervention group
Group type: COMPARATOR
Intervention: Sham (water)-treated clothing
Number of subjects: 1000
Study 27685606 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen inhalation challenge
Number of subjects: 14
Study 27685606 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐25 stimulation in vitro
Number of subjects: 14
Study 27685606 — intervention group
Group type: COMPARATOR
Intervention: Neutralizing IL‐25 antibody
Number of subjects: 14
Study 23620250 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion
Number of subjects: 45
Study 23620250 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐jaw orthognathic surgery
Number of subjects: 45
Study 22072378 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg Astaxanthin (AXT) per day for 4 weeks
Number of subjects: 20
Study 22072378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15765454 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral and sciatic nerve blocks
Number of subjects: 0
Study 15765454 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral nerve block
Number of subjects: 0
Study 11889194 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol x kg(‐1) x min(‐1))
Number of subjects: 9
Study 11889194 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 9
Study 11889194 — intervention group
Group type: COMPARATOR
Intervention: NaCl (placebo)
Number of subjects: 9
Study 9520605 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (8-week program with mail materials and 6 structured telephone counseling sessions)
Number of subjects: 125
Study 9520605 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention (single 5-minute telephone call and educational information)
Number of subjects: 125
Study 9520605 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 125
Study 7866682 — intervention group
Group type: COMPARATOR
Intervention: CATEGO syndrome SD (subjective feelings of depression) during first admission
Number of subjects: 51
Study 7866682 — intervention group
Group type: COMPARATOR
Intervention: CATEGO syndrome DD (depressive delusions)
Number of subjects: 51
Study 7866682 — intervention group
Group type: COMPARATOR
Intervention: Higher educational attainment
Number of subjects: 51
Study 7866682 — intervention group
Group type: COMPARATOR
Intervention: CATEGO syndromes SD and OD (biological features of depression)
Number of subjects: 51
Study 7866682 — intervention group
Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 51
Study 7866682 — intervention group
Group type: COMPARATOR
Intervention: Occupational outcome
Number of subjects: 51
Study 2491459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 19
Study 2491459 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 19
Study 2491459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 590301 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 49
Study 590301 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 49
Study 590301 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 49
Study 590301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclothiazide
Number of subjects: 49
Study 590301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31075459 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid intervention
Number of subjects: 178
Study 31075459 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 178
Study 29993130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide
Number of subjects: 100
Study 29993130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide with hyaluronidase
Number of subjects: 100
Study 29993130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional verapamil hydrochloride
Number of subjects: 100
Study 29993130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional radiofrequency
Number of subjects: 100
Study 29993130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional radiofrequency with triamcinolone acetonide
Number of subjects: 100
Study 27495295 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually-tailored intervention promoting a Mediterranean-style dietary pattern and increased walking (Phase I)
Number of subjects: 339
Study 27495295 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (16 weekly group sessions or 5 group sessions and 10 phone calls) (Phase II)
Number of subjects: 339
Study 27495295 — intervention group
Group type: COMPARATOR
Intervention: Weight loss maintenance RCT (Phase III)
Number of subjects: 339
Study 23893093 — intervention group
Group type: EXPERIMENTAL
Intervention: Raman spectroscopy
Number of subjects: 0
Study 22374703 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative crooked nose
Number of subjects: 39
Study 22374703 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative straightening rhinoplasty
Number of subjects: 39
Study 22374703 — intervention group
Group type: COMPARATOR
Intervention: Normal faces
Number of subjects: 39
Study 22374703 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in nasal asymmetry by 1 point
Number of subjects: 39
Study 20579205 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-oriented intervention programme
Number of subjects: 158
Study 20579205 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 158
Study 18375878 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program (8 visits by a trained home nurse over 18 months)
Number of subjects: 330
Study 18375878 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 330
Study 16045368 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted self‐help nutrition and PA materials (Group 2)
Number of subjects: 1056
Study 16045368 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted self‐help nutrition and PA materials plus 4 telephone counseling calls based on motivational interviewing (MI) (Group 3)
Number of subjects: 1056
Study 16045368 — intervention group
Group type: COMPARATOR
Intervention: Standard educational materials (Group 1)
Number of subjects: 1056
Study 12164680 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosceles triangular backgrounds (asymmetrically oriented with vertex in I visual field)
Number of subjects: 0
Study 12164680 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosceles triangular backgrounds (fragments of the triangle)
Number of subjects: 0
Study 12164680 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric illusions
Number of subjects: 0
Study 10542973 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF DPI) 100 mcg b.i.d.
Number of subjects: 365
Study 10542973 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF DPI) 200 mcg b.i.d.
Number of subjects: 365
Study 10542973 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF DPI) 400 mcg b.i.d.
Number of subjects: 365
Study 10542973 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 168 mcg b.i.d.
Number of subjects: 365
Study 10542973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 7822648 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct immunofluorescence staining
Number of subjects: 0
Study 7822648 — intervention group
Group type: COMPARATOR
Intervention: Viral culture
Number of subjects: 0
Study 2213870 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-influence prevention program
Number of subjects: 37
Study 2213870 — intervention group
Group type: COMPARATOR
Intervention: Standard care curricula
Number of subjects: 37
Study 646474 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 118
Study 646474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 31248026 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formula (whey-based extensively hydrolyzed formula containing 2'fucosyl-lactose and lacto-N-neotetraose)
Number of subjects: 67
Study 31248026 — intervention group
Group type: COMPARATOR
Intervention: Control formula (currently marketed extensively hydrolyzed formula without HMO)
Number of subjects: 67
Study 31248026 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formula
Number of subjects: 67
Study 28300506 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + Cel (Celecoxib 400 mg twice a day for 1 year)
Number of subjects: 1245
Study 28300506 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + ZA + Cel (Zoledronic acid 4 mg for six 3-weekly cycles, then 4-weekly for 2 years, plus Celecoxib 400 mg twice a day for 1 year)
Number of subjects: 1245
Study 28300506 — intervention group
Group type: COMPARATOR
Intervention: SOC (Standard of care hormone therapy)
Number of subjects: 1245
Study 28300506 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + ZA + Cel (in men with metastatic disease)
Number of subjects: 1245
Study 25455832 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual and manipulative therapy (MMT) alone
Number of subjects: 83
Study 25455832 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation alone
Number of subjects: 83
Study 25455832 — intervention group
Group type: EXPERIMENTAL
Intervention: MMT plus rehabilitation
Number of subjects: 83
Study 25455832 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study 23910762 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM‐tailored print interventions
Number of subjects: 4178
Study 23910762 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4178
Study 20688590 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldman tip procedure
Number of subjects: 100
Study 20688590 — intervention group
Group type: COMPARATOR
Intervention: Suture technique
Number of subjects: 100
Study 19830543 — intervention group
Group type: EXPERIMENTAL
Intervention: Half zona pellucida thinning
Number of subjects: 120
Study 19830543 — intervention group
Group type: COMPARATOR
Intervention: Quarter zona pellucida thinning
Number of subjects: 120
Study 16723326 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial Response Time Task (SRTT)
Number of subjects: 24
Study 16723326 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Grammar Learning (AGL)
Number of subjects: 24
Study 16723326 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Implicit Learning
Number of subjects: 24
Study 15337407 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day melarsoprol treatment
Number of subjects: 500
Study 15337407 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 500
Study 15337407 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative treatment (10-day melarsoprol)
Number of subjects: 500
Study 11177478 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 3 times/week
Number of subjects: 64
Study 11177478 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied once per day
Number of subjects: 64
Study 9342777 — intervention group
Group type: COMPARATOR
Intervention: triazolam (0.25 mg)
Number of subjects: 24
Study 9342777 — intervention group
Group type: EXPERIMENTAL
Intervention: capsule chosen (either placebo or triazolam)
Number of subjects: 24
Study 9342777 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 7933683 — intervention group
Group type: EXPERIMENTAL
Intervention: 201Tl reinjection SPECT with sublingual nitroglycerin (NTG)
Number of subjects: 80
Study 7933683 — intervention group
Group type: COMPARATOR
Intervention: 201Tl reinjection SPECT without sublingual nitroglycerin (NTG)
Number of subjects: 80
Study 3280125 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with retinol, riboflavin, and zinc
Number of subjects: 0
Study 3280125 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 3280125 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in retinol, riboflavin, and zinc blood levels
Number of subjects: 0
Study 29174754 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 46
Study 29174754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 26123704 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP inhibition with ciprofloxacin, ketoconazole, and paroxetine
Number of subjects: 16
Study 26123704 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP induction with rifampicin
Number of subjects: 16
Study 26123704 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no pretreatment)
Number of subjects: 16
Study 25916660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and exercise intervention
Number of subjects: 94
Study 25916660 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 23616514 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g/d L-tryptophan
Number of subjects: 17
Study 23616514 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g/d L-tryptophan
Number of subjects: 17
Study 23616514 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g/d L-tryptophan
Number of subjects: 17
Study 23616514 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 g/d L-tryptophan
Number of subjects: 17
Study 23616514 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 g/d L-tryptophan
Number of subjects: 17
Study 23616514 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 g/d)
Number of subjects: 17
Study 23616514 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (all doses)
Number of subjects: 17
Study 20943066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with monomeric allergoid (Lais, Lofarma) at three different maintenance doses
Number of subjects: 89
Study 20943066 — intervention group
Group type: COMPARATOR
Intervention: Medications only (control group)
Number of subjects: 89
Study 18548957 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular dentures retained by 1 or 2 implants
Number of subjects: 220
Study 18548957 — intervention group
Group type: COMPARATOR
Intervention: Screening process
Number of subjects: 220
Study 18548957 — intervention group
Group type: COMPARATOR
Intervention: Reasons for exclusion
Number of subjects: 220
Study 18548957 — intervention group
Group type: COMPARATOR
Intervention: Reasons for declining participation
Number of subjects: 220
Study 18548957 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for agreeing to participate
Number of subjects: 220
Study 16669406 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive reactive hyperemia (T30, T60, T120)
Number of subjects: 20
Study 12795787 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical access flap with enamel matrix derivative (EMD) application
Number of subjects: 11
Study 12795787 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical access flap alone (control)
Number of subjects: 11
Study 12795787 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical access flap with EMD application
Number of subjects: 11
Study 10650308 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Number of subjects: 0
Study 9715288 — intervention group
Group type: EXPERIMENTAL
Intervention: Medialisation osteotomy
Number of subjects: 138
Study 9715288 — intervention group
Group type: COMPARATOR
Intervention: Anatomical reduction
Number of subjects: 138
Study 1758327 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured clinical teaching
Number of subjects: 0
Study 1758327 — intervention group
Group type: COMPARATOR
Intervention: Traditional bedside teaching
Number of subjects: 0
Study 6857178 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) administration
Number of subjects: 8
Study 30844467 — intervention group
Group type: EXPERIMENTAL
Intervention: FLASH education
Number of subjects: 216
Study 30844467 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FLASH education)
Number of subjects: 216
Study 29428872 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril treatment
Number of subjects: 0
Study 27054838 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA)
Number of subjects: 0
Study 27054838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25062965 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Intervention (MI)
Number of subjects: 54
Study 25062965 — intervention group
Group type: COMPARATOR
Intervention: Self-Directed Intervention (C)
Number of subjects: 54
Study 22067790 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/drsp/levomefolate calcium
Number of subjects: 262
Study 22067790 — intervention group
Group type: COMPARATOR
Intervention: EE/drsp
Number of subjects: 262
Study 20850872 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Families New York (HFNY) home visiting program
Number of subjects: 522
Study 20850872 — intervention group
Group type: COMPARATOR
Intervention: Control group (referrals to other services)
Number of subjects: 522
Study 17208410 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA syrup (250mg)
Number of subjects: 15
Study 17208410 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA capsule (250mg)
Number of subjects: 15
Study 17208410 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium sprinkle capsule (250mg)
Number of subjects: 15